Inavolisib

{
  "id": "MLC-T-ONC-004258",
  "term": "Inavolisib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with palbociclib and fulvestrant to treat adults with certain types of hormone-receptor positive, HER2-negative breast cancer that has a mutation (change) in the PIK3CA gene. It is also being studied in the treatment of other types of cancer. Inavolisib works by blocking the activity of a protein called PI3K-alpha that signals cancer cells to multiply. It also helps break down mutant versions of this protein found in some cancer cells. This may keep cancer cells from growing and may kill them. Inavolisib is a type of targeted therapy drug called an enzyme inhibitor. Also called Itovebi.",
    "An orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. Upon administration, inavolisib binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Dysregulation of the PI3K signaling pathway is frequently associated with tumorigenesis and tumor resistance to a variety of antineoplastic agents and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is frequently mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion."
  ],
  "synonyms": [
    "Itovebi",
    "PI3K inhibitor GDC0077"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/inavolisib/"
}